LXEO Insider Trading Activity and SEC Form 4 Filings
LXEO insider trading summary
Over the past 12 months, insiders at Lexeo Therapeutics, Inc. (LXEO) reported 17 sales worth $752K by 7 insiders and no open-market purchases on SEC Form 4. Net insider selling was $752K.
Latest LXEO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 18, 2026 | Louis Edward Tamayo | Chief Financial Officer | Sell | $20K (4,117 @ $4.91) |
| Aug 18, 2026 | Richard Nolan Townsend | Chief Executive Officer | Sell | $17K (3,345 @ $4.95) |
| Aug 18, 2026 | Jose Manuel Otero | Chief Operating Officer | Sell | $6K (1,304 @ $4.96) |
| Jul 1, 2026 | Jose Manuel Otero | Chief Operating Officer | Sell | $21K (4,666 @ $4.48) |
| Jul 1, 2026 | Richard Nolan Townsend | Chief Executive Officer | Sell | $116K (25,947 @ $4.48) |
| Jul 1, 2026 | Louis Edward Tamayo | Chief Financial Officer | Sell | $21K (4,641 @ $4.49) |
| Jul 1, 2026 | Narinder Pal Bhalla | Chief Medical Officer | Sell | $99K (22,306 @ $4.42) |
| May 18, 2026 | Jose Manuel Otero | Chief Operating Officer | Sell | $7K (1,302 @ $5.07) |
| May 18, 2026 | Richard Nolan Townsend | Chief Executive Officer | Sell | $17K (3,342 @ $5.06) |
| Apr 6, 2026 | Richard Nolan Townsend | Chief Executive Officer | Sell | $313K (55,000 @ $5.69) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.